BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 3875390)

  • 1. Transient neurologic disturbances induced by high-dose methotrexate treatment.
    Jaffe N; Takaue Y; Anzai T; Robertson R
    Cancer; 1985 Sep; 56(6):1356-60. PubMed ID: 3875390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transient neurological disturbances induced by the chemotherapy of high-dose methotrexate for osteogenic sarcoma.
    Kiu MC; Liaw CC; Yang TS; Lai GM; Hsi SN; Lu CS
    Anticancer Drugs; 1994 Aug; 5(4):480-2. PubMed ID: 7949255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Evaluation of severe side effects of high-dose methotrexate in osteosarcoma].
    Umeda T; Takada N; Hodaka E; Endoh F; Ishii T
    Gan To Kagaku Ryoho; 1984 Feb; 11(2):285-94. PubMed ID: 6582805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Management of the administration of leucovorin calcium in high-dose methotrexate therapy].
    Kickinger W; Ritschl P; Kotz R
    Arzneimittelforschung; 1989 Jun; 39(6):728-31. PubMed ID: 2789050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Substitution of l-leucovorin for d,l-leucovorin in the rescue from high-dose methotrexate treatment in patients with osteosarcoma.
    Jaffe N; Jorgensen K; Robertson R; George M; Letvak L; Barrett G
    Anticancer Drugs; 1993 Oct; 4(5):559-64. PubMed ID: 8292813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose methotrexate with citrovorum factor rescue and adriamycin in childhood osteogenic sarcoma.
    Rosen G; Suwansirikul S; Kwon C; Tan C; Wu SJ; Beattie EJ; Murphy ML
    Cancer; 1974 Apr; 33(4):1151-63. PubMed ID: 4544836
    [No Abstract]   [Full Text] [Related]  

  • 7. "Single"-agent activity of high-dose methotrexate with citrovorum factor rescue.
    Von Hoff DD; Rozencweig M; Louie AC; Bender RA; Muggia FM
    Cancer Treat Rep; 1978 Feb; 62(2):233-5. PubMed ID: 305823
    [No Abstract]   [Full Text] [Related]  

  • 8. Progress report on high-dose methotrexate (NSC-740) with citrovorum rescue in the treatment of metastatic bone tumors.
    Jaffe N
    Cancer Chemother Rep; 1974; 58(2):275-80. PubMed ID: 4598245
    [No Abstract]   [Full Text] [Related]  

  • 9. High-dose methotrexate for osteosarcoma: toxicity and clinical results.
    Breithaupt H; Küenzlen E
    Oncology; 1983; 40(2):85-9. PubMed ID: 6600827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Weekly high-dose methotrexate-citrovorum factor in osteogenic sarcoma: pre-surgical treatment of primary tumor and of overt pulmonary metastases.
    Jaffe N; Frei E; Traggis D; Watts H
    Cancer; 1977 Jan; 39(1):45-50. PubMed ID: 299828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of l-leucovorin rescue following high-dose methotrexate for osteosarcoma.
    Goorin A; Strother D; Poplack D; Letvak LA; George M; Link M
    Med Pediatr Oncol; 1995 Jun; 24(6):362-7. PubMed ID: 7715542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose methotrexate with a safe rescue program.
    Decker DA; Edmonson JH; Gilchrist GS; Kovach JS; Offord JR; Taylor WF
    Oncology; 1981; 38(5):262-4. PubMed ID: 6973732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The influence of liver and renal functions on the changes in serum methotrexate (MTX) level in high-dose MTX therapy].
    Sato T; Nakanishi K; Takahashi M; Sato K; Miura T; Kuzuya T; Mizuno M
    Gan To Kagaku Ryoho; 1990 Dec; 17(12):2375-9. PubMed ID: 2260874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of intra-arterial cis-diamminedichloroplatinum II with high-dose methotrexate and citrovorum factor rescue in the treatment of primary osteosarcoma.
    Jaffe N; Robertson R; Ayala A; Wallace S; Chuang V; Anzai T; Cangir A; Wang YM; Chen T
    J Clin Oncol; 1985 Aug; 3(8):1101-4. PubMed ID: 3874932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma phenylalanine: tyrosine ratios during high-dose methotrexate-citrovorum "rescue".
    Hilton MA; Patel CC; Bertolone SJ; Kmetz DR; Clark LW
    Med Pediatr Oncol; 1982; 10(4):389-95. PubMed ID: 6981054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The effect of methotrexate pharmacokinetics and of leucovorin rescue on the prognosis of osteosarcoma].
    Graf N; Jost W; Müller J; Keller HE; Sitzmann FC
    Klin Padiatr; 1990; 202(5):340-6. PubMed ID: 2214594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Studies on the effect of high-dose methotrexate-citrovorum factor treatment for 89Sr induced osteosarcoma in mice (author's transl)].
    Nakamura T
    Nihon Seikeigeka Gakkai Zasshi; 1982 Feb; 56(2):149-61. PubMed ID: 6978919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Favorable response of metastatic osteogenic sarcoma to pulse high-dose methotrexate with citrovorum rescue and radiation therapy.
    Jaffe N; Paed D; Farber S; Traggis D; Geiser C; Kim BS; Das L; Frauenberger G; Djerassi I; Cassady JR
    Cancer; 1973 Jun; 31(6):1367-73. PubMed ID: 4541163
    [No Abstract]   [Full Text] [Related]  

  • 19. [Effects of hydration on plasma concentrations of methotrexate in patients with osteosarcoma treated with high doses of methotrexate].
    Ferrari S; Orlandi M; Avella M; Caldora P; Ferraro A; Ravazzolo G; Bacci G
    Minerva Med; 1992 May; 83(5):289-93. PubMed ID: 1589134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Experimental studies on high-dose methotrexate with citrovorum factor chemotherapy for 89Sr-induced osteosarcoma murine model.
    Tomita K
    Jpn J Antibiot; 1986 May; 39(5):1219-27. PubMed ID: 3489843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.